ALT
ALT clinical trials: Altimmune, Inc.
Every trial on ClinicalTrials.gov where Altimmune, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 20
- Trials linked
- 20
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ALT on the catalyst calendar · ALT registry changes
- Primary completion Dec 2028Sponsor estimatePhase 3NCT07795164Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASHAltimmune, Inc. · Metabolic Dysfunction-Associated Steatohepatitis (MASH)RecruitingALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2027Sponsor estimatePhase 2NCT07009860RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)Altimmune, Inc. · Alcohol-associated Liver DiseaseActive, not recruitingALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2026ActualPhase 2NCT06987513RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With...Altimmune, Inc. · Alcohol Use Disorder (AUD)CompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 25, 2025ActualPhase 2NCT05989711IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)Altimmune, Inc. · Non-Alcoholic Steatohepatitis (NASH)CompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 27, 2024ActualPhase 2NCT04684914HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)Altimmune, Inc. · Hepatitis B, ChronicTerminatedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 3, 2023ActualPhase 1NCT05134662ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)Altimmune, Inc. · Type 2 DiabetesCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 15, 2022ActualPhase 1NCT04972396Pemvidutide (ALT-801) DDI Study in Healthy VolunteersAltimmune, Inc. · NASH - Nonalcoholic SteatohepatitisCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2021ActualPhase 1NCT04561245ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityAltimmune, Inc. · ObesityCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 15, 2021ActualPhase 1NCT04415749NasoShield in Healthy Adults to Study Safety and ImmunogenicityAltimmune, Inc. · Healthy VolunteersCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 18, 2019ActualNo phase registeredNCT03760549Study of the Safety and Immunogenicity of NasoVAX ExtensionAltimmune, Inc. · InfluenzaCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 13, 2019ActualPhase 1NCT03352466NasoShield Study of Safety and ImmunogenicityAltimmune, Inc. · Healthy VolunteersCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2009ActualPhase 1NCT00755703Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.Altimmune, Inc. · Influenza A Subtype H5N1 InfectionCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2017ActualPhase 1NCT02496897Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis BAltimmune, Inc. · Hepatitis BCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 7, 2018ActualPhase 2NCT03232567Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAXAltimmune, Inc. · InfluenzaCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2023ActualPhase 2NCT05295875Efficacy and Safety of ALT-801 in the Treatment of ObesityAltimmune, Inc. · Obesity/OverweightCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2021ActualPhase 1NCT04679909Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)Altimmune, Inc. · Healthy VolunteersCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2022ActualPhase 1NCT05292911Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)Altimmune, Inc. · Non-Alcoholic Fatty Liver DiseaseCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 17, 2022ActualPhase 1NCT05006885ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)Altimmune, Inc. · Non-Alcoholic Fatty Liver DiseaseCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 15, 2021ActualPhase 2NCT04442230NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)Altimmune, Inc. · Coronavirus InfectionTerminatedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 21, 2017ActualPhase 4NCT03163342Immune Response Following Seasonal Influenza VaccinationAltimmune, Inc. · InfluenzaCompletedALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 20 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner